KRYS Quote, Financials, Valuation and Earnings

Mirum Pharmaceuticals has a net margin of 49.9% compared to Krystal Biotech's net margin of -23.93%. Krystal Biotech's return on equity of 10.49% beat Mirum Pharmaceuticals's return on equity of -37.59%.

Krystal Biotech has a consensus price target of $214.80, signalling upside risk potential of 20.59%. On the other hand Mirum Pharmaceuticals has an analysts' consensus of $63.89 which suggests that it could grow by 47.79%. Given that Mirum Pharmaceuticals has higher upside potential than Krystal Biotech, analysts believe Mirum Pharmaceuticals is more attractive than Krystal Biotech.

Krystal Biotech has a beta of 0.751, which suggesting that the stock is 24.867% less volatile than S&P 500. In comparison Mirum Pharmaceuticals has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.33300000000001%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. Mirum Pharmaceuticals pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $91.1M, which are smaller than Mirum Pharmaceuticals quarterly revenues of $99.4M. Krystal Biotech's net income of $45.5M is higher than Mirum Pharmaceuticals's net income of -$23.8M. Notably, Krystal Biotech's price-to-earnings ratio is 59.58x while Mirum Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 18.21x versus 6.70x for Mirum Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 49.9% compared to Krystal Biotech's net margin of -49.65%. Krystal Biotech's return on equity of 10.49% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Krystal Biotech has a consensus price target of $214.80, signalling upside risk potential of 20.59%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 51.17%. Given that NovaBay Pharmaceuticals has higher upside potential than Krystal Biotech, analysts believe NovaBay Pharmaceuticals is more attractive than Krystal Biotech.

Krystal Biotech has a beta of 0.751, which suggesting that the stock is 24.867% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $91.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Krystal Biotech's net income of $45.5M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Krystal Biotech's price-to-earnings ratio is 59.58x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 18.21x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 49.9% compared to Krystal Biotech's net margin of -2357.27%. Krystal Biotech's return on equity of 10.49% beat Palatin Technologies's return on equity of --.

Krystal Biotech has a consensus price target of $214.80, signalling upside risk potential of 20.59%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1222.25%. Given that Palatin Technologies has higher upside potential than Krystal Biotech, analysts believe Palatin Technologies is more attractive than Krystal Biotech.

Krystal Biotech has a beta of 0.751, which suggesting that the stock is 24.867% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $91.1M, which are larger than Palatin Technologies quarterly revenues of $350K. Krystal Biotech's net income of $45.5M is higher than Palatin Technologies's net income of -$2.4M. Notably, Krystal Biotech's price-to-earnings ratio is 59.58x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 18.21x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of 49.9% compared to Krystal Biotech's net margin of --. Krystal Biotech's return on equity of 10.49% beat Theriva Biologics's return on equity of --.

Krystal Biotech has a consensus price target of $214.80, signalling upside risk potential of 20.59%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 408.48%. Given that Theriva Biologics has higher upside potential than Krystal Biotech, analysts believe Theriva Biologics is more attractive than Krystal Biotech.

Krystal Biotech has a beta of 0.751, which suggesting that the stock is 24.867% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $91.1M, which are larger than Theriva Biologics quarterly revenues of --. Krystal Biotech's net income of $45.5M is higher than Theriva Biologics's net income of -$4.4M. Notably, Krystal Biotech's price-to-earnings ratio is 59.58x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 18.21x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.